HepaCure for acute-on-chronic liver failure
Part of Digestive system clinical trials.
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You weigh at least 40 kilograms (about 88 pounds)
- You have been diagnosed with acute-on-chronic liver failure that is in the early or middle stage
- You do not have liver cancer or a high risk of bleeding in the esophagus/stomach
- You do not have a serious uncontrolled infection or severe kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
This trial tests whether adding mesenchymal stem cells to a blood-cleaning procedure helps people with acute liver failure recover. It may reduce inflammation and improve liver function.
This trial tests whether stem cells from donated umbilical cords can help people with acute-on-chronic liver failure, a sudden worsening of chronic liver disease. The goal is to see if this treatment improves liver function and survival.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
This trial tests a procedure that filters harmful substances from your blood using a special machine. It is for people with severe liver failure (acute-on-chronic) who have signs of inflammation throughout the body.
This trial tests a new liver dialysis device called DIALIVE 2.0 for people with acute-on-chronic liver failure (a sudden, severe worsening of chronic liver disease). If you qualify, the device will help filter your blood, similar to kidney dialysis, to support your liver while it tries to recover.
Hear when a new Acute on Chronic Hepatic Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.